Crown Equity Holdings Inc. (OTCBB:CRWE) announced recently that it has launched its crwenewswire.fr website to provide news in France’s native language. Crown Equity Holdings Inc. had previously launched its German website crwenewswire.de and is launching its Canadian website crwenewswire.ca shortly.
“The new website is one step in many towards the company goal of expanding its footprint internationally, ” commented Kenneth Bosket, President and CEO of Crown Equity Holdings Inc. “Our goal for 2010 is to have all CRWE’s clients’ press releases, articles and news content published in every major financial country’s native language, as well as within cities of every state of our country,” stated Mr. Bosket.
Crown Equity Holdings Inc. is a consulting organization which provides and assists small business owners with the knowledge required in taking their company public, and has re-focused its primary vision with its aligned group of independent website divisions to providing media advertising services, as a worldwide online media advertising publisher, dedicated to the distribution of quality branding information, as well as search engine optimization for its clients.
Neuralstem, Inc. (NYSE Amex: CUR) announced that its spinal cord stem cells survived in rat brains affected by stroke and differentiated predominantly into neurons. The transplanted animals showed significant improvement in some motor skill and strength measurements. The study entitled, “Intracerebral Implantation of Adherent Human Neural Stem Cells To Reverse Motor Deficits in Chronic Stroke Rats,” was presented earlier today by senior study author, Dr. Shinn-Zong Lin, M.D., Ph.D., at the Stem Cells USA & Regenerative Medicine Conference, in Philadelphia, PA. Dr. Lin is a Professor of Neurosurgery and Vice Superintendent at China Medical University Hospital of Taiwan.
“This animal study shows the potential promise of this cell line in treating post-stroke symptoms,” Dr. Lin commented. “Four weeks after transplantation, the rats treated with Neuralstem’s cells showed significantly decreased asymmetric body swing, increased vertical movements and increased grip strength, compared with the control group.”
“Dr. Lin’s findings represent a significant milestone for Neuralstem. They are the first to show how our human spinal cord-derived stem cell product, NSI-566RSC, currently in a clinical trial for ALS, and which we expect to be in another clinical trial for spinal cord injury, also works in the stroke brain,” said Dr. Karl Johe, Ph.D., Neuralstem’s Chief Scientific Officer and Chairman of the Board of Directors. “Our proposed treatment for paralysis due to stroke will involve transplantation near the motor tracts close to the stroke lesion in the brain in order to promote regeneration and repair. While the trial protocol for ALS and chronic spinal cord injury involves transplantation into the spinal cord, and that for stroke will involves transplantation into the brain, we are nevertheless targeting the circuitry that controls motor function in each indication. We are developing clinical programs for stroke in both the U.S. and Taiwan, and hope to start our first trial in 2011.”
NeurogesX, Inc. (Nasdaq: NGSX) reports that on or about the filing date of its upcoming Quarterly Report on Form 10-Q for the quarter ended June 30, 2010, it intends to file a universal shelf registration statement on Form S-3 with the Securities and Exchange Commission (SEC).
This shelf registration statement is planned to give NeurogesX the ability to offer and sell from time to time up to an aggregate of $75,000,000 of its securities, which may consist of common stock, preferred stock, debt securities, warrants, or depositary shares. The terms of any offering under the shelf registration statement will be determined at the time of offering. While NeurogesX does not have any immediate plans to offer securities under this shelf registration, it is intended to give NeurogesX the flexibility to take advantage of financing opportunities as needed or deemed desirable in light of market conditions.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any security and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offering, solicitation or sale would be unlawful. The offering of NeurogesX securities under the universal shelf registration will be made only by means of a prospectus.
NeurogesX, Inc. is a San Francisco Bay Area-based biopharmaceutical company focused on developing and commercializing novel pain management therapies. NeurogesX was founded on the concept that use of prescription-strength capsaicin could help manage the pain associated with neuropathic pain conditions. Since its inception, NeurogesX has leveraged its passion to help people with pain to efficiently develop this concept, resulting in the commercial launch of Qutenza (capsaicin) 8% patch in 2010. The Company continues to apply its knowledge and expertise in the development of other novel treatments for pain.
Neustar, Inc. (NYSE: NSR) reports the launch of Ultra DDI, a new offering that seamlessly integrates internal DNS, DHCP and IP Address Management (IPAM) operations. Ultra DDI allows Neustar customers to outsource their entire infrastructures while allowing them to retain full control over day-to-day changes.
“IT managers are now recognizing how critical IPAM and DNS are to their service delivery,” said Glenn O’Donnell, senior analyst at Forrester in his report Inquiry Spotlight: Network Monitoring and Management, Q1 2009. “Expanded attention beyond the network often highlights IP and DNS failures as the root cause of service failures, and [IT managers] are learning that discipline in IPAM and DNS is mandatory.”
The Neustar Ultra DDI managed service includes networking equipment using Infoblox appliances, as well as issue resolution, software updates, equipment replacement and hardware lifecycle replenishment. In addition, Neustar experts conduct around-the-clock monitoring and maintenance of back-end DNS and DHCP operations, watching nearly 50 health and usage parameters for proactive infrastructure management and issue response. Neustar also retains a database of critical DNS and DHCP data points to enable trending and planning for future growth and management.
“Neustar exists to simplify network complexity,” said Alex Berry, senior vice president of Neustar’s Internet Infrastructure Services (IIS) group. “DNS and DHCP are the linchpins for unifying networks and enhancing communications � and it is becoming increasingly time- and labor-intensive for our customers to juggle multi-vendor management and network troubleshooting on their own. More customers are realizing that it simply makes good business sense to trust Neustar. We have built a sterling reputation in delivering and managing the core services underlying IP network infrastructures.”
No comments:
Post a Comment